title: RAS mutation status and bortezomib therapy for relapsed multiple myeloma.
authors.affiliation: Department of Haematology, Cancer Institute, University College London, London, UK. dean.smith@ucl.ac.uk.
authors.forename: Dean
authors.initials: D
authors.lastname: Smith
authors.affiliation: London Research Institute, London, UK.
authors.forename: Elena
authors.initials: E
authors.lastname: Armenteros
authors.affiliation: Department of Haematology, Cancer Institute, University College London, London, UK.
authors.forename: Laura
authors.initials: L
authors.lastname: Percy
authors.affiliation: London Research Institute, London, UK.
authors.forename: Madhu
authors.initials: M
authors.lastname: Kumar
authors.affiliation: Department of Haematology, Cancer Institute, University College London, London, UK.
authors.forename: Anna
authors.initials: A
authors.lastname: Lach
authors.affiliation: Department of Haematology, Cancer Institute, University College London, London, UK.
authors.forename: Gaelle
authors.initials: G
authors.lastname: Herledan
authors.affiliation: Department of Haematology, Cancer Institute, University College London, London, UK.
authors.forename: Matthew
authors.initials: M
authors.lastname: Stubbs
authors.affiliation: London Research Institute, London, UK.
authors.forename: Julian
authors.initials: J
authors.lastname: Downward
authors.affiliation: Department of Haematology, Cancer Institute, University College London, London, UK.
authors.forename: Kwee
authors.initials: K
authors.lastname: Yong
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D000069286:Bortezomib; D011905:Genes, ras; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D009154:Mutation; D009364:Neoplasm Recurrence, Local; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib
keywords: RAS mutation; bortezomib; multiple myeloma; prognosis